| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/02/2005 | EP1501496A2 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 02/02/2005 | EP1501495A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
| 02/02/2005 | EP1501494A1 Cell proliferating agents |
| 02/02/2005 | EP1501493A1 Use of epa and dha in secondary prevention |
| 02/02/2005 | EP1501492A1 ANTI- i RHINOVIRUS /i ACTIVE AGENTS |
| 02/02/2005 | EP1501491A2 Methods and compositions for treatment of cancer pain |
| 02/02/2005 | EP1501490A2 Methods of simultaneously treating mucositis and fungal infection |
| 02/02/2005 | EP1501489A1 Combination therapy for the treatment of cancer |
| 02/02/2005 | EP1501488A1 USE OF GABA sb B /sb RECEPTOR POSITIVE MODULATORS IN GASTRO-INSTESTINAL DISORDERS |
| 02/02/2005 | EP1501487A1 Capsule preparation |
| 02/02/2005 | EP1501486A1 Extended release tablets comprising felodipine |
| 02/02/2005 | EP1501485A1 High drug load tablet |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501479A1 Capsules for dry powder inhalers and methods of making and using same |
| 02/02/2005 | EP1501478A1 Warming and nonirritating anhydrous lubricant compositions |
| 02/02/2005 | EP1501467A2 Heterocyclo inhibitors of potassium channel function |
| 02/02/2005 | EP1501359A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 02/02/2005 | EP1501352A1 Methods and compositions for controlled release of drugs |
| 02/02/2005 | EP1404334A4 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 02/02/2005 | EP1390365B1 Novel sulfonate substituted pyrazol pyridine dervivatives |
| 02/02/2005 | EP1379257A4 Prodrugs of anticancer agents employing substituted aromatic acids |
| 02/02/2005 | EP1373267B1 Non-nucleoside reverse transcriptase inhibitors |
| 02/02/2005 | EP1363642A4 Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion |
| 02/02/2005 | EP1362050B1 Pyrimidine derivatives for inhibition of cell-proliferation |
| 02/02/2005 | EP1330233B1 Method of treating stroke |
| 02/02/2005 | EP1318820B1 Medicament containing sub-anesthetic concentrations of xenon for use in the treatment of cardiovascular diseases |
| 02/02/2005 | EP1305016B1 Use of n-oleoylethanolamine for treating psoriasis |
| 02/02/2005 | EP1303521B1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 02/02/2005 | EP1303506B1 6-heteroarylphenanthridines |
| 02/02/2005 | EP1292591B1 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 02/02/2005 | EP1280812B1 Cyclipostins, a method for their production and the use of the same |
| 02/02/2005 | EP1259550B1 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 02/02/2005 | EP1242395B1 Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
| 02/02/2005 | EP1235574B1 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 02/02/2005 | EP1218009B1 Quetiapine granules |
| 02/02/2005 | EP1181283B1 Diaminothiazoles and their use for inhibiting protein kinases |
| 02/02/2005 | EP1165534B1 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments |
| 02/02/2005 | EP1165042B1 Drinkable ibuprofen pharmaceutical suspension |
| 02/02/2005 | EP1161235B1 Combinations for the treatment of diseases involving angiogenesis |
| 02/02/2005 | EP1137413B1 Non-peptide antagonists of glp-1 receptor and methods of use |
| 02/02/2005 | EP1135166B9 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/02/2005 | EP1131104B1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 02/02/2005 | EP1130966B1 Antiparasitic formulations |
| 02/02/2005 | EP1124779B1 Vitamin d analogues |
| 02/02/2005 | EP1119248B1 Hydroxystilbene compounds used as microbicidal active substances |
| 02/02/2005 | EP1025079B1 $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| 02/02/2005 | EP1023077B1 Opthalmic composition |
| 02/02/2005 | EP1011688B1 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
| 02/02/2005 | EP1007017B1 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
| 02/02/2005 | EP1001760B1 Composition for controlling mood disorders in healthy individuals |
| 02/02/2005 | EP0981610B1 Compositions for treatment of disorders involving programmed cell death |
| 02/02/2005 | EP0966534B1 Compositions and methods for elimination of unwanted cells |
| 02/02/2005 | EP0957915B1 Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
| 02/02/2005 | EP0912575B1 Processes for the synthesis of chemical compounds having pde-iv inhibitory activity |
| 02/02/2005 | EP0862633B1 Virus protein antigens of the jc virus |
| 02/02/2005 | EP0852585B1 Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
| 02/02/2005 | EP0851769B1 Gene therapy using ovine adenoviral vectors |
| 02/02/2005 | EP0847275B1 Regulation of intracellular glucocorticoid concentrations |
| 02/02/2005 | EP0832227B1 Method for prolonging the expression of a gene of interest using soluble ctla4 molecules |
| 02/02/2005 | EP0828754B1 Dipeptides which promote release of growth hormone |
| 02/02/2005 | EP0757557B1 Methods for inducing t cell tolerance to a tissue or organ graft |
| 02/02/2005 | EP0729357B1 Microencapsulated 1,2-benzazoles |
| 02/02/2005 | CN1575341A Method for preparing heparin from mast cell cultures |
| 02/02/2005 | CN1575337A Mammalian receptor proteins; related reagents and methods |
| 02/02/2005 | CN1575292A Pharmaceutically acceptable salts of 20(s)-camptothecins |
| 02/02/2005 | CN1575291A Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 02/02/2005 | CN1575290A Pyrimidine derivatives and pharmaceutical compositions containing that compounds |
| 02/02/2005 | CN1575289A 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same |
| 02/02/2005 | CN1575286A Thiophene-amd thiazolesulfonamides as antineoplastic agents |
| 02/02/2005 | CN1575284A Substituted triazole diamine derivatives as kinase inhibitors |
| 02/02/2005 | CN1575283A Piperazine derivatives with CCRI receptor antagonist activity |
| 02/02/2005 | CN1575282A Lactam compound |
| 02/02/2005 | CN1575280A Urea and thiourea derivatives as non-nucleoside reverse transcriptase inhibitors |
| 02/02/2005 | CN1575279A Substituted thioacetamides |
| 02/02/2005 | CN1575273A 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor antagonists |
| 02/02/2005 | CN1575191A Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors |
| 02/02/2005 | CN1575189A Stent, process for production thereof and its use for treating for restenosen and/or trombozen |
| 02/02/2005 | CN1575185A Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| 02/02/2005 | CN1575184A Method and composition for treating immune complex associated disorders |
| 02/02/2005 | CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/02/2005 | CN1575181A Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders |
| 02/02/2005 | CN1575180A Antidiabetic 2-substituted-5'-o- (1-boranotriphosphate) adenosine derivatives |
| 02/02/2005 | CN1575179A Combination product comprising melagatran and dexamethasone |
| 02/02/2005 | CN1575178A Method and composition for treatment of ocular hypertension and glaucoma |
| 02/02/2005 | CN1575177A Cxcr3 antagonists |
| 02/02/2005 | CN1575176A Process for making substituted pyrazoles |
| 02/02/2005 | CN1575175A Drug formulation having improved oral tolerability |
| 02/02/2005 | CN1575174A Pharmaceutically active isoindoline derivatives |
| 02/02/2005 | CN1575173A Macrolides containing pharmaceutical compositions |
| 02/02/2005 | CN1575172A Substituted ideno[1, 2-c]isoquinoline derivatives and methods of use thereof |
| 02/02/2005 | CN1575171A Novel anti-diabetic agents |
| 02/02/2005 | CN1575170A (-)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 02/02/2005 | CN1575169A Mch antagonists for the treatment of obesity |
| 02/02/2005 | CN1575168A Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 02/02/2005 | CN1575167A Method for treatment of reactive arthritis or bursitis |
| 02/02/2005 | CN1575166A Preventive and/or therapeutic agent for viral infection |
| 02/02/2005 | CN1575165A Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
| 02/02/2005 | CN1575163A Granule formulation |
| 02/02/2005 | CN1575162A Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin |
| 02/02/2005 | CN1575133A Process and composition for controlling fecal hair excretion and trichobezoar formation |